share_log

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6

HC Wainwright & Co.维持对Akebia Therapeutics的买入,将目标股价上调至6美元
Moomoo 24/7 ·  03/28 12:20

HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target from $5 to $6.

HC Wainwright & Co. 分析师埃德·阿尔塞维持Akebia Therapeutics(纳斯达克股票代码:AKBA)的买入并将目标股价从5美元上调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发